Department of Psychology and Sociology, University of Zaragoza, Zaragoza, Spain.
Trials. 2013 Jan 3;14:3. doi: 10.1186/1745-6215-14-3.
Fibromyalgia is a prevalent chronic rheumatic disease of great clinical importance. Recent studies have found raised levels of glutamate in the insula, hippocampus and posterior cingulate cortex regions of the brains of fibromyalgia (FM) patients. This finding has led researchers to speculate about the usefulness of glutamate-blocking drugs such as memantine in the treatment of fibromyalgia. The hypothesis of this study is that the administration of memantine will reduce the glutamate levels, and futhermore, will decrease the perceived pain. The aim of this study is to evaluate the efficacy of memantine in the treatment of pain (pain perception). A secondary objective is to evaluate the efficacy of memantine in the treatment of other clinical symptoms of FM, and to evaluate the efficacy of memantine in reducing brain levels of glutamate, and its effects on the central nervous system as a whole.
METHOD/DESIGN: A double-blind parallel randomized controlled trial. Participants, Seventy patients diagnosed with FM will be recruited from primary health care centers in Zaragoza, Spain. Intervention. The subjects will be randomized in two groups: A) A treatment group (n = 35), which will receive 20 mg of memantine daily; B) A control group (n = 35), to which will be administered a placebo. There will be a six-month follow-up period (including a titration period of one month). Outcomes. The main efficacy variable of this study is pain (pain perception). The secondary efficacy variables are clinical symptoms (pain threshold, cognitive function, health status, anxiety, depression, clinical impression and quality of life) and glutamate levels in different regions of the brain, which will be assessed by magnetic resonance spectroscopy. Randomization and blinding. Randomization has been computer-generated, and the random allocation sequence will be implemented by telephone. Subjects of the study and the research assistants will be blinded to group assignment.
There is a need for the development of innovative and more effective treatments for fibromyalgia. This clinical trial will determine whether memantine can be an effective pharmacological treatment for fibromyalgia patients.
Current Controlled Trials http://ISRCTN45127327 EUDRACT 2011-006244-73.
纤维肌痛是一种常见的慢性风湿性疾病,具有重要的临床意义。最近的研究发现,纤维肌痛(FM)患者大脑的脑岛、海马体和后扣带回皮质区域谷氨酸水平升高。这一发现促使研究人员推测使用谷氨酸阻断药物如美金刚治疗纤维肌痛的有效性。本研究的假设是,美金刚的给药将降低谷氨酸水平,并进一步降低感知疼痛。本研究的目的是评估美金刚治疗疼痛(疼痛感知)的疗效。次要目标是评估美金刚治疗纤维肌痛其他临床症状的疗效,评估美金刚降低大脑谷氨酸水平的疗效及其对整个中枢神经系统的影响。
方法/设计:一项双盲平行随机对照试验。参与者:将从西班牙萨拉戈萨的初级保健中心招募 70 名被诊断为纤维肌痛的患者。干预措施:受试者将随机分为两组:A)治疗组(n=35),每日接受 20mg 美金刚;B)对照组(n=35),给予安慰剂。将进行为期 6 个月的随访(包括一个月的滴定期)。结局:本研究的主要疗效变量是疼痛(疼痛感知)。次要疗效变量是临床症状(疼痛阈值、认知功能、健康状况、焦虑、抑郁、临床印象和生活质量)以及大脑不同区域的谷氨酸水平,将通过磁共振波谱进行评估。随机化和盲法:随机化已通过计算机生成,随机分配序列将通过电话实施。研究对象和研究助理将对分组分配不知情。
需要开发创新的、更有效的纤维肌痛治疗方法。本临床试验将确定美金刚是否可以成为纤维肌痛患者有效的药物治疗方法。
当前对照试验,http://ISRCTN45127327;EUDRACT 2011-006244-73。